Navigation Links
Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
Date:3/11/2013

LA JOLLA, Calif., March 11, 2013 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Mayo Clinic signed a new collaborative agreement to build a pipeline of therapeutic drugs aimed at a variety of diseases with serious unmet medical needs. Under this agreement, Mayo Clinic scientists will work with researchers in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (Prebys Center) to conduct early-stage drug discovery, including assay development, high-throughput screening, and lead identification. Sanford-Burnham, an independent research institute, is recognized for establishing novel collaborations with clinical organizations to expedite early-phase drug discovery.

The agreement combines Mayo Clinic's clinically relevant targets with Sanford-Burnham's discovery platform in a translational initiative aimed at advancing a portfolio of projects through the initial stages of drug discovery. The new agreement builds on a yearlong pilot phase and expands the number and scope of drug discovery projects derived from Mayo Clinic researchers that are being conducted at Sanford-Burnham.

"We're looking forward to further engaging with our Mayo Clinic collaborators as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets," said Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "If successful, these compounds will form the basis of completely novel'first in class'therapies for devastating diseases such as cancer, Alzheimer's, and others."

In Sanford-Burnham's Prebys Center, Jackson and a team of researchersmany of them recruited from the pharmaceutical industryuse state-of-the-art, ultra-high throughput screening systems to sift through the Institute's compound library, recognized as one of the largest collections in the nonprofit research community.

"The Mayo Clinic-Sanford-Burnham collaboration provides an avenue for Mayo scientists to rapidly translate basic science discoveries into screening platforms that will enable new drug discovery, and a new paradigm in drug development," said Andrew Badley, M.D., associate dean of research resources at Mayo Clinic.

Kristiina Vuori, M.D., Ph.D., Sanford-Burnham's president and interim CEO, agreed, adding that "this collaborative model provides interactions between researchers with deep expertise in drug discovery technologies, basic research scientists and clinical scientists that will expedite the drug discovery process and offer a clinical outlet for testing potential new drugs."


'/>"/>
Contact: Heather Buschman
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Source:Eurekalert  

Related biology news :

1. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
2. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
3. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
4. Californias stem cell agency boosts heart disease research at Sanford-Burnham
5. Promiscuous enzymes may be recruited to aid industry, medical fields
6. WPI Biomedical Technology in final 4 of international business plan contest
7. 3 Johns Hopkins researchers recognized for medical inventions
8. Breakthrough study opens door to broader biomedical applications for Raman spectroscopy
9. Medbox Partners with Bio-Tech Medical Software to Create Nations Safest Prescription Drug and Medical Marijuana Distribution System
10. Sex and gender competency essential to medical care
11. Hastings Center resources chart progress in debate over medical research with animals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sanford-Burnham Medical Research Institute and Mayo Clinic  extend collaborative agreement
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... 2017 , ... The HealthTech Venture Network (HTVN) is proud ... annual Conference where founders, investors, innovative practitioners and collaborators are invited to a ... early stage digital health and med tech companies. , This day-long event will ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading ... around the world, is giving back to cancer research with a month-long promotion supporting ... Now through October 31, shoppers can use promo code PinkRibbon to get 10 percent ...
(Date:10/5/2017)... ... October 05, 2017 , ... NIH has awarded Circulomics two ... DNA/RNA extraction technology . Nanobind is a novel magnetic disk that contains a ... be used for a wide variety of sample preparation applications. The nanostructured surface ...
Breaking Biology Technology: